

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 October 2024 (17.10.2024)



(10) International Publication Number
WO 2024/215948 A1

(51) International Patent Classification:

A61K 51/10 (2006.01) *A61K 103/30* (2006.01)
A61P 35/00 (2006.01) *A61K 103/40* (2006.01)
A61K 103/20 (2006.01)

(21) International Application Number:

PCT/US2024/024155

(22) International Filing Date:

11 April 2024 (11.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/495,561 12 April 2023 (12.04.2023) US

(71) Applicants: **FUSION PHARMACEUTICALS INC.** [CA/CA]; 270 Longwood Road South, Hamilton, Ontario L8P 0A6 (CA). **ASTRAZENECA UK LIMITED** [GB/G-B]; 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB).

(72) Inventor; and

(71) Applicant: **MONLISH, Darlene Anne** [US/US]; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).

(72) Inventors: **CAICEDO, David Rodriguez**; 357 Raymond Road, Ancaster, Ontario L9K 0J8 (CA). **TURNBULL, William Leslie**; 1119 Cooke Boulevard, Apt B226, Burlington, Ontario L7T 0C7 (CA). **MAHAMMAD, Saleemulla**; 194 Whittington Dr., Ancaster, Ontario L9K 0H5 (CA). **VAN DYK, Dewald**; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **MUNIZ-MEDINA, Vanessa Marie**; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **SALLADA, Nathanael David**; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **CHEUNG, Sao Fong**; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **HAN, Jeong Min**; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **COMER, Frank Irvine**; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **WORREDE, Asurayya**; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **CHANG, Chien-ying**; 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).

(74) Agent: **JACOBSTEIN, Jeffrey M.** et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New

York Avenue, NW, Washington, District of Columbia 20001-4413 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: STEAP2-TARGETED COMPOUNDS AND USE THEREOF

(57) Abstract: The present disclosure provides compounds or pharmaceutically acceptable salts thereof, e.g., radioimmunoconjugates including a chelating moiety or a metal complex thereof, a linker, and an antibody or antigen-binding fragment thereof targeting STEAP2. The present disclosure also provides pharmaceutical compositions of such compounds or pharmaceutically acceptable salts thereof and methods of treatment for conditions, e.g., cancer, using such compounds, pharmaceutically acceptable salts thereof, or pharmaceutical compositions.

WO 2024/215948 A1